Multidisciplinary Care Coordination Team for Heart Failure

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
George Washington University Medical Faculty Associates, Washington, United States
Heart Failure+3 More
Multidisciplinary Care Coordination Team - Behavioral
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

Several drugs have been labeled as guideline-directed-medical therapies (GDMT) to improve overall health outcomes and slow the progression of disease in patients with heart failure (HF). Although scientific trials have deemed these drugs to be successful, many HF patients have been unable to either get started on the appropriate drug regimens or be optimized on the doses required to show substantial benefit, particularly in those who also suffer from chronic kidney disease (CKD). This is largely due to the current health care delivery model that requires a primary care clinician or general internist to refer patients to heart failure specialists and nephrologists. The specialty care itself then requires even more coordination resulting in patients getting lost to follow-up, physicians losing track of recommendations from different clinics, and too many separate electronic medical documentations to consolidate prior to deciding on what medication is appropriate at one thirty-minute outpatient visit. This study plans to create a new, virtual cardio-renal multidisciplinary team including a heart failure specialist and nephrologist to ease the coordination of care and consequently show a better implementation of GDMT in patients with HF and CKD when comparing those rates to the traditional referral-based way that these medications get prescribed.

Eligible Conditions

  • Heart Failure
  • Chronic Kidney Disease (CKD)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: 6 months

6 months
Difference in rate of sodium glucose co-transporter 2 inhibitors (SGLT2i)
Heart failure hospitalizations
Quality of life of patients-Cardiomyopathy Questionnaire
Quality of life of patients-Kidney Disease Questionnaire

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Control
1 of 2
Intervention
1 of 2
Active Control
Experimental Treatment

160 Total Participants · 2 Treatment Groups

Primary Treatment: Multidisciplinary Care Coordination Team · No Placebo Group · N/A

Intervention
Behavioral
Experimental Group · 1 Intervention: Multidisciplinary Care Coordination Team · Intervention Types: Behavioral
ControlNoIntervention Group · 1 Intervention: Control · Intervention Types:

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 6 months
Closest Location: George Washington University Medical Faculty Associates · Washington, United States
Photo of washington 1Photo of washington 2Photo of washington 3
2004First Recorded Clinical Trial
2 TrialsResearching Heart Failure
32 CompletedClinical Trials

Who is running the clinical trial?

George Washington UniversityLead Sponsor
197 Previous Clinical Trials
110,684 Total Patients Enrolled
Janai Rangaswami, MDPrincipal InvestigatorFellowship program director for the Division of Nephrology, Director of the cardiorenal program

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.